Cite
MLA Citation
Matthew D. Seftel et al.. “The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.” Leukemia & lymphoma, vol. 58, no. 6, 2017, pp. 1358–1365. http://access.bl.uk/ark:/81055/vdc_100042870833.0x00000f